A Case of Acute Stent Thrombosis During Treatment with the Thrombopoietin Receptor Agonist Peptide—Romiplostim

Rayoo, R.; Sharma, Naveen; Gaal, William J. van

doi:10.1016/j.hlc.2011.09.001

Cited by 9 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pretreatment with steroids, IVIG, and platelets was required in 52%, 27%, and 13% of cases, respectively. Danazol [ 6 , 7 ] was used in two cases and romiplostim in two other cases [ 3 , 8 ]. The platelet at the time of intervention was only known in 15 patients.…”

Section: Discussionmentioning

confidence: 99%

“…In general individual case reports have shown that aspirin and clopidogrel are well tolerated even chronically when platelet count is above 30 × 10 9 /L [ 17 ]. Among those cases, 14 patients were discharged on aspirin [ 7 , 8 , 13 – 22 ], 15 patients received clopidogrel [ 6 – 8 , 13 – 23 ], while two patients received abciximab, [ 8 , 14 ] and two others received eptifibatide [ 8 , 18 ]. One patient received ticlopidine [ 24 ] and three patients did not receive any antiplatelets [ 3 , 25 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two Cases and Review of the Literature: Primary Percutaneous Angiography and Antiplatelet Management in Patients with Immune Thrombocytopenic Purpura

et al. 2013

View full text Add to dashboard Cite

We report two cases of immune thrombocytopenic purpura (ITP) associated with acute coronary artery syndrome highlighting the interventions done in every case along with the medications used during intervention and as outpatient. The first case is that of a woman with ITP exacerbation while on dual antiplatelet therapy and the second case is that of a male presenting with non-ST elevation myocardial infarction (NSTEMI) while in a thrombocytopenic crisis. In both cases antiplatelet therapy was held and thrombopoietic therapy was initiated before resuming full anticoagulation and coronary intervention. Given the paucity of data on ITP and antiplatelets treatment in the setting of acute coronary syndrome, no strict recommendations can be proposed, but antiplatelets appear to be safe acutely and in the long term in this category of patients as long as few measures are undertaken to minimize the risks of bleeding and thrombosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Two Cases and Review of the Literature: Primary Percutaneous Angiography and Antiplatelet Management in Patients with Immune Thrombocytopenic Purpura

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Besides, a number of treatment modalities for ITP increase susceptibility to thrombotic events due to either abrupt rise of the platelet count with emergence of immature prothrombotic platelets (rituximab, IVIg) or increased plasma viscosity (IVIg, platelet transfusion) or metabolic changes which promote atherosclerosis (steroids) [2]. The thrombopoietin receptor agonists (TPO-RA) and danazol are also related to thrombotic complications [7].…”

Section: Discussionmentioning

confidence: 99%

Challenge of Using Antiplatelet Drugs in Patients with Primary Immune Thrombocytopenia and Recently Implanted Coronary Stents-Splenectomy as a Therapeutic Option

Marisavljević¹,

Marković²,

Zdravković³

et al. 2017

Adv Pharmacoepidemiol Drug Saf

View full text Add to dashboard Cite

Background: Immune thrombocytopenic purpura (ITP) in the patients with implanted coronary stents is related with serious risks of haemorrhage related to dual antiplatelet therapy on the one hand and stent thrombosis if antiplatelet therapy is interrupted on the other hand. Therefore, the main objective in these patients is the correction of thrombocytopenia and continuous use of antiplatelet drugs.

show abstract

“…As an additional proof, renal TMA has recently been reported with another second-generation thrombopoietic agent, eltrombopag. 30 Thrombotic events, including deep vein thrombosis, myocardial infarction, coronary stent thrombosis, septic thrombophlebitis, transient ischemic attack, and portal vein thrombosis have been described in patients treated with romiplostim [31][32][33][34][35] and occurred mostly in those with pre-existing thrombotic risk factors. In 76% of cases, thrombotic events were seen when platelet count was below 400 K/CUM.…”

Section: Development Of Ttp In a Patient With Pre-existing Slementioning

confidence: 99%

Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim

Tomov

Lazarchick

Self

et al. 2013

Lupus

View full text Add to dashboard Cite

We present the case of a 19 year-old Caucasian female with history of systemic lupus erythematosus (SLE) and normal baseline kidney function who developed severe acute renal failure following treatment of thrombocytopenia with the thrombopoietic agent romiplostim. Percutaneous kidney biopsy revealed thrombotic microangiopathy (TMA) without immune complex lupus glomerulonephritis. We discuss pathogenesis and differential diagnosis of TMA in patients with SLE and raise concerns regarding the use of thrombopoietic agents in such patients. Based on favorable long-term outcome in our case aggressive treatment and in particular prolonged use of plasma exchange in these patients are advocated.

show abstract

A Case of Acute Stent Thrombosis During Treatment with the Thrombopoietin Receptor Agonist Peptide—Romiplostim

Cited by 9 publications

References 4 publications

Two Cases and Review of the Literature: Primary Percutaneous Angiography and Antiplatelet Management in Patients with Immune Thrombocytopenic Purpura

Two Cases and Review of the Literature: Primary Percutaneous Angiography and Antiplatelet Management in Patients with Immune Thrombocytopenic Purpura

Challenge of Using Antiplatelet Drugs in Patients with Primary Immune Thrombocytopenia and Recently Implanted Coronary Stents-Splenectomy as a Therapeutic Option

Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim

Contact Info

Product

Resources

About